Key Points
- Director Christopher Brown sold 8,358 shares of 908 Devices at an average price of $9.23, worth about $77,144. The transaction occurred under a pre-arranged Rule 10b5-1 plan, and he retained 805,559 shares.
- 908 Devices reported a better-than-expected quarter, with a loss of $0.11 per share versus the $0.14 consensus estimate and revenue of $16.07 million versus $15.37 million expected. Management also raised the low end of its 2026 revenue outlook to $68 million.
- Analyst sentiment is mixed: two firms rate the stock Buy while others maintain Hold or Sell ratings, resulting in an average Hold rating and a consensus price target of $12.50. Institutional investors own 88.06% of the company.
908 Devices Inc. (NASDAQ:MASS - Get Free Report) Director Christopher Brown sold 8,358 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $9.23, for a total value of $77,144.34. Following the completion of the sale, the director owned 805,559 shares of the company's stock, valued at approximately $7,435,309.57. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
908 Devices Stock Up 0.1%
MASS stock opened at $10.02 on Thursday. 908 Devices Inc. has a 52 week low of $5.03 and a 52 week high of $10.52. The business has a 50-day simple moving average of $8.26 and a 200 day simple moving average of $7.36. The company has a market cap of $378.86 million, a PE ratio of -10.55 and a beta of 0.66.
908 Devices (NASDAQ:MASS - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.29%. The company had revenue of $16.07 million during the quarter, compared to analysts' expectations of $15.37 million. On average, analysts anticipate that 908 Devices Inc. will post -0.4 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have weighed in on MASS. Roth Capital raised their target price on 908 Devices from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday. Stifel Nicolaus upped their price objective on 908 Devices from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday. Wall Street Zen cut shares of 908 Devices from a "buy" rating to a "hold" rating in a report on Saturday, July 18th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of 908 Devices in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $12.50.
Get Our Latest Stock Report on MASS
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of MASS. First Light Asset Management LLC grew its holdings in shares of 908 Devices by 92.6% during the fourth quarter. First Light Asset Management LLC now owns 4,836,186 shares of the company's stock worth $25,390,000 after purchasing an additional 2,325,690 shares during the last quarter. BlackRock Inc. acquired a new stake in 908 Devices during the 2nd quarter worth approximately $16,915,000. Granahan Investment Management LLC grew its holdings in 908 Devices by 662.6% during the 1st quarter. Granahan Investment Management LLC now owns 695,070 shares of the company's stock worth $4,254,000 after acquiring an additional 603,929 shares during the last quarter. Needham Investment Management LLC grew its holdings in 908 Devices by 246.8% during the 4th quarter. Needham Investment Management LLC now owns 770,000 shares of the company's stock worth $4,042,000 after acquiring an additional 548,000 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of 908 Devices by 359.4% during the second quarter. Marshall Wace LLP now owns 648,796 shares of the company's stock valued at $4,626,000 after acquiring an additional 507,562 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.
Trending Headlines about 908 Devices
Here are the key news stories impacting 908 Devices this week:
- Positive Sentiment: Q2 earnings and revenue exceeded expectations. 908 Devices reported a loss of $0.11 per share, better than the $0.14 consensus loss, while revenue reached $16.07 million versus estimates of $15.37 million. Revenue increased 23% year over year, and the company said its adjusted EBITDA loss narrowed by more than half from the prior year. 908 Devices Reports Second Quarter 2026 Financial Results
- Positive Sentiment: Management raised the low end of its full-year outlook. 908 Devices now expects 2026 revenue of $68 million to $70 million, compared with the previous outlook’s lower starting point and roughly in line with the $68.6 million analyst consensus. The company’s guidance excludes potential AVCAD contribution from its core outlook, which may leave room for upside if that business contributes. 908 Devices Signals 2026 Revenue Outlook
- Positive Sentiment: Growth drivers remain intact. Demand for chemical-detection instruments from law enforcement, defense, and other mission-critical customers, along with recurring NIRLab revenue and upgrades such as VipIR, is supporting the bullish view. One analyst publication maintained a BUY rating after the earnings beat. 908 Devices Mission Critical Devices Drive Growth
- Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference, providing an opportunity for management to discuss its outlook and growth strategy. 908 Devices to Present at the Midwest IDEAS Investor Conference
- Negative Sentiment: Director Christopher D. Brown sold a combined 17,800 shares for approximately $162,000 across August 10 and 11. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their negative signaling value, and Brown still owns 805,559 shares after the transactions. 908 Devices SEC Insider Trading Filing
About 908 Devices
(
Get Free Report)
908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company's core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.
Key products in 908 Devices' portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
